Repeated administration of long acting analogues of gonadotrophin releasing hormone diminishes gonadal function and in men decreases testosterone concentrations; for this reason the effect of the analogue buserelin was studied in prostatic carcinoma. Twelve consecutive patients with newly diagnosed locally advanced or metastatic carcinoma of the prostate were treated. Each patient received intranasal buserelin in divided dosages of either 600 or 1000 ,ug daily. Suppression of the gonadotrophins and testosterone occurred in all patients. Objective and subjective signs of regression of disease were seen in nine patients.
Introduction
It is 40 years since the original observation that orchidectomy could produce a sustained remission in prostatic cancer. Subsequently many hormone treatments have been described that induce a high incidence of initial response and symptomatic relief, but each has disadvantages and none confers a survival of stilboestrol is the most commonly used, but the incidence of intolerance may reach 40% and mortality may be 20% in patients with previous myocardial ischaemia. 3 Chemotherapy has no useful role,46 and only the antiandrogen progestogen cyproterone acetate appears to be as effective as stilboestrol, with fewer side effects. 6 A radically different approach, without apparent toxicity, is the use of highly potent analogues of gonadotrophin releasing hormone. Although initially promoting increased secretion of gonadotrophin, with long term use these analogues decrease synthesis and secretion of gonadotrophin, leading to a fall in gonadal hormone concentrations.7 8 In addition, there may be a direct inhibitory effect on the gonad.9 Effectively, in men the pituitary-testicular axis is down regulated. Initially, workers were most interested in the contraceptive application of these compounds, and most experience in Europe has been with buserelin (D-ser6-ter-butyl-gonadotrophin-releasing hormoneethylamine).7 8 In view of the hormonal dependence of prostatic cancer the usefulness of these analogues in the management of this tumour is of interest. A preliminary clinical study of 10 patients treated with either D-ala6-GnRH ethylamine or buserelin was encouraging.10 We report a detailed prospective study of 12 consecutive new patients with advanced disease treated with buserelin for up to nine months.
Patients and methods
Twelve patients gave informed consent to be treated in this study. All had histologically proved symptomatic advanced prostatic cancer for which no specific treatment had been given. Three patients had previously had myocardial infarcts. Treatment was given for between one and nine months. Isotope bone scanning-Eight patients had evidence of bone metastases. Four (cases 2, 6, 7, and 10) showed improvement with treatment, but none achieved a normal scan.
Acid phosphatase activity was initially raised in six patients (cases 2, 4, 5, 7, 10, and 12) and became normal in five (cases 2, 5, 7, 10, and 12) within one to three months (mean 14 months). One patient (case 4), who had an undifferentiated tumour, had a persistently raised acid phosphatase activity, which did not improve. In case 5 the symptoms failed to respond to treatment but normal acid phosphatase activity was achieved. 4 0 ng/ml)) to 5 0 nmol/l (1-4 ng/ml) (range 3 6-6-4 nmol/l (1-0-1-8 ng/ml)) with the 600 sIg regimen and by 73% from 9-9 nmol/l (2-9 ng/ml) (range 3-1-12 5 nmol/l (0 9-3-6 ng/ml)) to 2-7 nmol/l (08 ng/ml) (range <25-39 nmol/l (<07-1 1 ng/ml)) with the 1000 ,ug regimen (Wilcoxon's rank sum test on unpaired samples p < 0-05). With the 1000 jig regimen concentrations seen in castrated patients were reached by the fourth treatment week. Luteinising hormone-After one month's treatment the mean luteinising hormone concentration had decreased by 59%/) from 8-8 U/I (range 1-8-23-5 U/1) to 3 6 U/I (range 2-2-6-0 U/1) (p <0 01). There was no difference in concentration between patients who did and did not respond or between the 600 jig and 1000 /ig regimens.
Follicle stimulating hormone-After one month's treatment the median concentration of follicle stimulating hormone had decreased by 42°O from 5-7 U/I to 3-3 U/I (not significant). There was no difference in concentrations between patients who did and did not respond or between the 600 ,ug and 1000 jig regimens. 1 7-[-Oestradiol-After one month's treatment the mean 17-noestradiol concentration had decreased by 25%) from 137 pmol/l to 103 pmol/l (p<005). A significant difference (p<005) was found when the changes in concentrations produced by the two treatment regimens were compared: the mean 17-3-oestradiol concentration decreased by 10%' from 132 pmol/l to 119 pmol/l with the 600 ,ug regimen and by 49%/' from 164 pmol/l to 83 pmol/l with the 1000 ,ug regimen. Oestrogen concentrations were not different between patients who did and did not respond.
Prolactin-After one month's treatment the mean prolactin concentration had decreased by 560 from 292 mU/l to 129 mU/l (p < 0-05). No significant difference was found between patients who did and did not respond or between the 600 jig and 1000 ,ug regimens.
Progesterone, growth hormone, and sex hormone binding globulin concentrations did not change significantly with treatment.
SIDE EFFECTS OF TREATMENT
All of the patients complained of inability to attain erections. They also noted that facial flushing occurred from one to six times daily; this was mild and lessened in intensity and frequency as the duration of treatment increased.
Discussion
This study has shown that buserelin, the long acting analogue of gonadotrophin releasing hormone, suppressed secretion of testosterone and gonadotrophin in advanced prostatic cancer, improving several of the symptoms and signs-namely, bone pain, urinary frequency, lymphatic obstruction, nodal deposits, leucoerythroblastic anaemia, and cord compression-often to the point of complete resolution.
A hypothalamic factor, a decapeptide originally described in 1969, releases both luteinising hormone and follicle stimulating hormone.13 Its release from the hypothalamus is pulsatile, and this pulsatility is important for both the synthesis and secretion of the gonadotrophins by the pituitary.14 Subsequently, substituted analogues of gonadotrophin releasing hormone were described that seemed to possess greatly enhanced potency.'5 It was initially thought that these analogues would be of clinical use in syndromes of gonadotrophin deficiency,'6 but this was not so because the mechanism of action of long acting analogues of gonadotrophin releasing hormone is paradoxical. After initial stimulation down regulation of the pituitary and finally also the gonad occurs, resulting from the prolonged binding of the analogues to pituitary receptors.'7 Thus the gonadotrophin analogues have a clinical role in suppressing gonadal activity, and they have been used as contraceptives'8 and in endometriosis,"9 in precocious puberty,"0 and breast cancer."
In a previous series of patients the clinical effect of superactive gonadotrophin analogues in prostatic cancer was assessed. In six patients with locally advanced disease and four with metastatic prostatic cancer were given D-Trp6-substituted analogues subcutaneously and D-ser6-substituted analogues subcutaneously or intranasally. Evidence of response was observed in nine patients.' 0 It is not obvious which effect of treatment is important in mediating response. In our patients response did not relate to concentrations of circulating gonadotrophins, testosterone, or oestradiol, and this is true also for treatment with oestrogens or castration.
This study clearly established that buserelin is as effective, at least in the short term, as stilboestrol or orchidectomy. Its advantages over other medical treatment are that it is specific in terms of suppression of gonadotrophin and gonadal steroids, obviates the need for surgery, and is without major side effects. Its long term efficacy requires evaluation and comparison with that of stilboestrol.
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Introduction
Occipital neuralgia was recognised in the nineteenth century and descriptions of the condition may be found in contemporary textbooks. It was attributed to an "affection" of the great occipital nerve until Charles Toogood Downing observed that "the Earl of . . ., a nobleman of strong constitution, was not relieved of cervico-occipital neuralgia when the sub-occipital nerve was divided by Mr Syme." This led Downing to suggest that occipital neuralgia was due to damage to the second cervical nerve.' A century later Hunter and Mayfield provided the anatomical explanation why the second cervical nerves are particularly susceptible to trauma.2 Unlike the other spinal nerves, they are not protected by bony pedicles and facets. Their ganglia lie on the vertebral arch of the axis and the nerves pass between the arches of the atlas and the axis to the soft tissues in the neck. Hence they are clearly vulnerable and may be crushed when the two bony surfaces are approximated by forced hyperextension of the head. They may also be injured when excessive rotation occurs in one direction and the arches of the atlas and axis exert a scissor like action on the ipsilateral nerve. Thus both hyperextension and excessive rotation may result in injury to one or both of the second cervical nerves. Wrenching movements of the head are particularly dangerous since they combine both movements.
Case report
A young waitress was a front seat passenger when her car was hit at high speed by another car coming from the opposite direction. She was not wearing a seat belt and was thrown forward and upward and then violently backwards. She was taken to hospital complaining of severe headache and dizziness and her neck was immobilised in a collar. She returned to work three months later. She was still having symptoms, however, which were in the form of sharp, intermittent headaches originating in the nape of the neck and radiating to the right temple and dizzy spells associated with nausea and loss of balance. (On one occasion when she was spooning cream on to a customer's pudding she suddenly lurched to one side and spilt cream all over his tie.) Examination showed diminished sensation to pin prick in the territory of the right second cervical spinal nerve and tenderness over the right great occipital nerve.
Review of 17 cases of post-traumatic neuropathy of the second cervical spinal nerve disclosed 12 that were caused by similar such acceleration-deceleration road traffic accidents. In the remainder the initiating trauma was less severe, and in two patients the injury occurred when the head was violently turned to one side to avoid a threat to the eyes.
Comment
Injury to the second cervical spinal nerve is associated with sensory aberrations usually associated with disturbances of equilibrium. The sensory aberrations range from loss of sensation to severe neuralgia, and the pain is often burning or stabbing. It tends to be intermittent, and associated with superficial tenderness of the scalp, which may be noticed on brushing the hair. The sensory changes may be hemicranial or localised to fixed areas within the distribution of the second cervical nerve -for example, periorbital, temporal, suboccipital, or, in rare cases, around the ear or at the angle of the jaw. Tenderness on palpation of the greater occipital nerve is common. The condition is usually unilateral, and in the rare cases of bilateral nerve damage the sensory abnormalities are usually asymmetrical.
